Category Archives: Press Releases

Current press release information from the Mesothelioma Research Foundation of America, particularly regarding Veglin, FDA Phase III clinical trials.

What Mesothelioma Treatments Are Available?

Currently, mesothelioma treatments include chemotherapy treatments, radiation treatments, surgical treatments and experimental therapies and drugs. Research news reports the limited success of present treatments for Mesothelioma.

Mesothelioma research news indicates that traditional treatments viz. single or multi-drug chemotherapy has a response rate of about 20%. Radiation treatments, usually used in conjunction with surgery or chemotherapy treatments can relieve pain and shrink tumors, making breathing easier. However, radiation treatments can also cause severe side effects.

Efforts To Treat Mesothelioma Cancer

Mesothelioma can take between ten and sixty years to develop after inhalation of respirable asbestos fibers, but Mesothelioma progresses fast. Radical surgeries as mesothelioma treatments have had limited success. Surgical treatments attempted include extra-pleural pneumonectomy (EPP) and pleurectomy.

Recent news about mesothelioma treatments  indicates that in EPP over 15% patients die soon after surgery. EPP involves removal of pleura, diaphragm, pericardium, part of the phrenic nerve and the entire tumor-affected lung and has to be supported by chemotherapy or radiation.

The pleurectomy treatments involve removal of the pleura without removing the whole lung. These treatments are best in patients with good lung expansion who tend to accumulate fluid. In combination with radiation pleurectomy is reported in treatment news to have given 22-month survival in 50% and 24-month survival in 41% cases in a 27-patient group with mesothelioma of the epithelial subtype.

Surgical treatments of mesothelioma have not been shown to offer significant advantages over the limited non-surgical treatments. Experimental drugs under evaluation include treatments by Onconase, Lovastatin and an Endostatin and angiostatin combination.

USC Norris Comprehensive Cancer Center with Veglin treatment for Mesothelioma
Dr. Parkash S. Gill and Veglin treatment for Mesothelioma cancer

 

 

The Mesothelioma Research Foundation of America is funding research by Dr. Parkash S. Gill on a mesothelioma cure. Dr. Gill, working at the USC Norris Comprehensive Cancer Center in Los Angeles, has completed Phase I Clinical Trials his new mesothelioma treatment drug called Veglin. Continued research and Phase II Clinical trials of Veglin have begun in July 2004, opening exciting treatment possibilities with a cure for mesothelioma victims.

Understanding the Diagnosis and Treatment of Mesothelioma

What is malignant mesothelioma?

Mesothelioma, better known as malignant mesothelioma is a form of cancer that affects people who have been exposed to asbestos by working in an environment where they are exposed to and breathed in the asbestos particles, or they have lived in a home containing asbestos. Many people have lived in an environment with asbestos particles floating around and were not aware of it.

Malignant mesothelioma frequently starts out in the chest; one breathes in the sharp hooked particles-look like fish hooks when viewed under a microscope-however asbestos fibers can be ingested with food and drink.

The most common form of mesothelioma is plural mesothelioma. Asbestos particles are inhaled, the particles hook into the lungs. From there the particles slowly work their way to infiltrate the plural lining, which is the sac that contains the lungs. The patient cannot excrete these fibers; they stay within the body, because they are durable.

The body tries to fight the foreign particles that have taken up residence in the body. The asbestos particles cause irritation and as a result cancerous tumors start to develop. The plural form of the disease is very aggressive.

If you have been diagnosed with malignant mesothelioma, you have a cancer of the serous membranes, which are the membranes of glandular cells that secrete serous fluid. Serous membranes in the plural cavity allow the lungs to move with inhalation and expiration smoothly without friction. Many people have the have the disease, or know someone that has the disease have the misconception that mesothelioma is a primary form of lung cancer, but it isn’t. The cancerous tumors develop in the plural cavity. As the tumors grow there is less space in the plural cavity and the lungs become compressed. With lung compression comes respiratory failure.

What is peritoneal mesothelioma?

Peritoneal mesothelioma is cancer of the lining, the serous membranes, of the abdominal cavity. The serous membranes line the cavity and also line the organs. The serous membranes that cover the organs is also called the viscera, or visceral membranes. Peritoneal mesothelioma is the second most common type of mesothelioma. The cause of peritoneal mesothelioma is not clearly understood; however, it is believed the asbestos fibers get to the abdominal cavity two different ways.

It is believed that when a person inhales the asbestos fibers that over time the fibers break apart into smaller particles and find their way into circulation, and then as the blood vessels become smaller the particles work their way through the vessels and into different areas of the body. One such place is the peritoneum, but mesothelioma can develop in the testicles and other parts of the body.

The other theory is that the home is infiltrated with asbestos particles. When the person works in an environment the particles are all over the clothes and float in the air on dust particles. The kitchen are can become loaded with floating particles, and the particles can also settle on plates, glasses and silverware. It is believed that a person can ingest the particles. When they do swallow the asbestos particles they work their way through the stomach lining and invade the lining of the abdomen and the lining of the organs. Once the particles become lodged the peritoneal cavity they cause chronic irritation and then the tumors begin to grow.

What is testicular mesothelioma?

Mesothelioma of the testicles is a rare form. It is believed that asbestos fibers travel from the stomach to the peritoneum and through to the testicles, because the lining of the testicles is an out-pouching of the abdominal peritoneal lining.

Misconceptions

Mesothelioma is sometimes called asbestos lung cancer, or asbestosis. Both terms are incorrect. Mesothelioma is not lung cancer, the disease does not cause tumors in the lungs. The tumors are in the plural lining that surrounds the lungs and compresses them until the patient goes into respiratory failure.

Asbestosis is caused by the inhalation of asbestos fibers. They become stuck in the lungs and cause irritation, but does not cause cancerous tumors. This is a very serious lung disease that mimics the symptoms of asthma and emphysema. It is not to be confused with mesothelioma. As the cancer develops in the peritoneum, the serous membranes rapidly secretes fluid into the abdominal area, which causes pain and discomfort as the organs become compressed. Patients are often symptomatic for approximately 6 months before a diagnosis of peritoneal mesothelioma is made.

Staging

There is no staging system specific to mesothelioma; however, the staging is the same as is done with other forms of cancer, which is the TNM system-(T) tumor, (N) lymph nodes, (M) metastasis. The first stage (Tumor) indicates a lesion that has developed into a tumor. The second stage (Lymph Nodes) indicates that the tumors are contained within the organ surfaces and the lining of the abdomen. The third stage (Metastasis) indicates cancer cells are leaving the tumor and invading other organs of the body. Once metastasis has occurred the disease is difficult to treat.

Prognosis and treatment

Treatment of mesothelioma depends on the location and stage, and it also depends on the condition of the patient, because patients are often told their survival rate is between 8 and 12 months. Although there are special cancer centers around the country that do have better statistics. There are three types of treatments to treat mesothelioma: surgery, chemotherapy, and radiation therapy. Very often it takes more than one form of treatment, such as surgery with radiation or chemotherapy with radiation. Surgery normally does not remove all of the cancer from the body. Time is of the essence in the prognosis and treatment of mesothelioma. When the cancer has metastasized to other organs it is much more difficult to treat.

Treating Mesothelioma

Treating Mesothelioma

Mesothelioma is a cancerous disease that affects the serous linings of various internal organs in the human body. Among them, the lungs, heart and the stomach are widely affected.

It is estimated that each year 2,000 new cases of mesothelioma are diagnosed. The patients suffering from this cancerous disease have prior exposure to asbestos, which is considered to be the only known cause of mesothelioma. Mesotheliomic patients are often told of their short survival duration of 6 – 12 months, but doctors specialized in treating malignant mesothelioma at leading cancer centers expect more. Though mesothelioma causes immense pain and suffering to the victim, along with short life expectancy, certain treatments have resulted in the successful reduction and removal of the cancerous tumors of mesothelioma.

In this article, we will elaborate on the significant treatments available to patients suffering from the asbestos- related cancer (mesothelioma).

Please be advised that only a professional doctor specializing in cancer can diagnose mesothelioma. It is recommended for patients suffering from the symptoms of mesothelioma, to consult a cancer specialist for a possible treatment. After examining medical reports and asbestos-exposure history, the doctor can announce the preliminary diagnosis. The doctor can also conduct a needle biopsy to finalize the diagnosis of malignant mesothelioma. For more relevant and latest Mesothelioma Information and diagnosing mesothelioma, check out: http://www.mesorfa.org/

 Additionally, it is noteworthy that the treatment of mesothelioma depends on many factors, including the stage of the cancer, the circulation of the malignant cells, pathology reports determining the nature of the cancer cells and patient’s age and health.

Following are the mesothelioma treatment options available to the patients for treating the cancer:

  • Surgery
  • Chemotherapy
  • Radiation or Radiotherapy
  • Immunotherapy
  • Clinical Trails
  • Complementary Therapy
  • Nutrition
  • Fitness and Exercise
  • Meditation and Stress Reduction

Treating mesothelioma is not an easy task.

It requires immense pain endurance and patience. Nonetheless, with proper treatment and medications, along with the love and support from the family members and friends, mesothelioma can be controlled.

Mesothelioma Symptoms and Treatment Options

Three Potential Peritoneal Mesothelioma Symptoms and Treatment Options

Mesothelioma is one of the less common types of cancer affecting approximately 2000 people each year. It develops when the linings of the lungs or the abdomen start to grow in a rapid and uncontrollable way.  This cancer is almost always caused by exposure to asbestos particles and therefore has been nicknamed asbestos cancer. When it affects the lining of the abdomen (the peritoneum) it is referred to as peritoneal mesothelioma. In this article we will be discuss three (3) common symptoms for mesothelioma cancer and share the steps you should take when you notice any of these.

The peritoneum (lining of the abdomen) actually has two layers; the inner (visceral) layer which is beside the abdominal organs and the outer (parietal) layer which is next to the abdominal wall.

One of the functions of the peritoneum is to secrete a lubricating fluid to allow the abdominal organs to move against one another. When peritoneal mesothelioma occurs it leads to both of these layers becoming thicker. This can then lead to a number of undesirable symptoms including:

    1. ASCITES – As the inner and outer layers of the peritoneum become thicker, lubricating fluid can become trapped in this area. This can then lead to a build up of fluid which is referred to as ascites. Ascites can lead to swelling in the abdomen and also cause abdominal pain as the build up of fluid causes the peritoneum to press against the abdominal organs.
    2. ABDOMINAL PAIN – As peritoneal mesothelioma develops and the tumour increases in size it can start to press against the abdominal organs. This often causes abdominal pain and discomfort. As discussed above ascites (another peritoneal mesothelioma symptom) can also lead to abdominal pain.
    3. POOR BOWEL FUNCTIONING – As the tumour increases in size or the ascites cause further swelling the intestines can become blocked. This can make it difficult to excrete waste from the body and also lead to further bowel problems.

When you discover any symptoms similar to those discussed above you should consult your doctor immediately. Upon seeing your doctor you should inform them of the symptoms you have experienced and also tell them if you have previously been in contact with asbestos. Once your doctor has this information they will be able to perform the required tests and determine whether you have peritoneal mesothelioma. Following this they can then discuss the relevant treatment options with you if necessary.

Mesothelioma is one of the rarest types of cancer. In most cases these symptoms will turn out to be something much less serious. However, by seeing your doctor you can get a professional opinion on whether you have, or do not have,  mesothelioma. When you have had persistent abdominal pains, your abdomen has become swollen or you have had regular bowel problems go see your doctor immediately!

This information is intended for general use only, while every effort has been made to make it accurate and informative.  Mesothelioma is a very serious, life threatening condition and you should discuss any concerns, treatments or lifestyle changes fully with your doctor.  

Mesothelioma Treatment Options

More info – Mesothelioma Treatments

Veglin is not released yet to restart it’s Phase 2 Clinical Trials

Today, Dr. Parkash Gill announced that Veglin is not released yet to restart it’s Phase 2 Clinical Trials, and the project continues to wait for FDA approval. Dr. Gill is working hard to restart Veglin within Phase 2 and is also working diligently to get EPH-B4 into Phase I Clinical Trials.

Please use our FaceBook link  to obtain your FREE copy of our eBook that teaches you 10 easy steps on how to find and choose a clinical trial for Mesothelioma and how to prepare for it!

Ask Dr. Gill about your specific mesothelioma issues here: Ask Dr. Gill

Learn more about Veglin at this cancer research link: read more…

In addition to the eBook found at our Facebook fan page, also learn more about clinical trials from these links:

Mesothelioma treatment – Veglin clinical trial – phase 2 resumes

August 21, 2011

Today, Dr. Parkash Gill announced that Veglin is again being released for continued Phase 2 Clinical Trials by FDA approval. According to Gill, the studies for Veglin should be open within the month. He has completed and turned in the protocol and detail as required which will allow Phase 2 clinical studies to soon start up again on Veglin. Also, a Phase 1 clinical study on Eph B4, Dr. Gills other molecule, should be available soon.

Mesothelioma treatment cure found in Veglin - phase 2 clinical trials

Ask Dr. Gill about mesothelioma treatment cure in Veglin

Ask Dr. Gill about the upcoming study of Veglin, Phase 2 clinical trials… Click Here

Learn about Veglin at this MesoRFA link: read more…

And learn about participating in a clinical trial at these MesoRFA links:

 

Dr. Parkash Gill announces Veglin waiting on further FDA aproval

Veglin waits for further FDA approval
Dr. Parkash Gill and Veglin wait for further FDA approval

PRESS RELEASE

April 30, 2011

Dr. Parkash Gill has announced that Veglin is not available until receiving FDA approval.  This delay is considered normal and a required process by the FDA. Once the FDA approves, Alimta Cisplatin chemotherapy along with Veglin (a non-chemotherapy) will be the next protocol used.

Veglin Drug as Mesothelioma Treatment for Cancer Cure enters National Phase III Clinical Trials

Summary:

A new drug, Veglin, is a mesothelioma treatment that acts as like an anti-angiogenesis agent that works by cutting off the blood supply that cancer cells require in order to grow.  The cancer cells are starved with no adverse effects to normal healthy cells.  Clinical Trials of Veglin for Phase I and II have been successful at stopping mesothelioma cancer.  National clinical trials of this drug for Phase III study by FDA approval are ready to launch in 2011.


Mesothelioma Research Foundation of America
Westlake Village, California
March 24, 2011

Veglin is set for Phase III of the FDA approval process but we are currently being held back by the funding needed.  Good news is we are at the beginning of our fundraising season and hope to generate the funds needed over the next couple of months with clay shoots and golf tournaments taking place between may and July of 2011.

The benefit of introducing Veglin into Phase III is we will be able to provide Veglin to any facility of hospital willing to administer it to mesothelioma patients.  This will broaden our patient base and speed the FDA approval process in making Veglin a “mainstream” treatment for mesothelioma.  As of today we are very localized, administering the drug only in Southern California at the USC Norris Comprehensive Center, but we hope to have this changed very soon.

It is amazing how far we have come in the last 9 years, operating on a budget that is a fraction of what most pharmaceutical companies will put into the development of new drugs.  This is all thanks to our friends in the Insulators Unions, D.C. 16 and Building Trades Councils who are always there lending support.

About Veglin

Veglin is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by Dr. Parkash Gill’s for the treatment of a variety of malignancies including mesothelioma. Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.

Veglin is an antisense oligonucleotide that binds with DNA genes that are responsible for the production of proteins called Vascular Endothelial Growth Factors (VEGF), with the intention of inhibiting their production. This new drug acts as like an anti-angiogenesis agent that works by cutting off the blood supply that cancer cells require in order to grow.  The cancer cells are starved with no adverse effects to normal healthy cells.

Veglin proved successful in FDA monitored Phase I and Phase II clinical trials.  Many patients suffering and dying from mesothelioma cancer are very hopeful for the possibilities of a more effective cancer treatment compared to what presently is available for mesothelioma victims.

About Mesothelioma Research Foundation of America

The Mesothelioma Research Foundation of America has a mission: fund research that will lead to the quickest cure for mesothelioma. Mesothelioma is a cancer of the lining of the lungs caused by asbestos exposure. This cancer disease had few treatment options until this Foundation and Dr. Parkash Gill’s work created better treatment options. Today, the future looks more hopeful for additional improved treatment options available to those stricken by this cancer.

The Foundation began funding research for a cure in 2001 with the opening of the Mesothelioma Laboratory at USC Norris Comprehensive Cancer Medical Center in Los Angeles under the supervision of Dr. Parkash Gill.

Dr. Gill is a board certified oncologist and hematologist who has received FDA approval from the U.S. Government to do Clinical Trials on a mesothelioma treatment drug called Veglin. We believe there is great promise and hope in Veglin and the Mesothelioma Research Foundation of America has funded 100% of Dr. Gill’s research.  Every dollar donated to the Foundation goes to the Phase III Clinical Trials of Veglin, a mesothelioma treatment.

Contact Information:

Shane Rucker
Mesothelioma Research Foundation of America
Toll Free:
(800) 909-Meso (6376)

Links:

Get their website information at:
http://mesorfa.org

Their blog is at:
http://mesorfa.info

Find them on FaceBook at:
http://facebook.mesorfa.org

National Asbestos Awareness Week with a New Hope for a Mesothelioma Treatment

National Asbestos Awareness Week will begin this year the first week of April.  Non-profit groups like the Mesothelioma Research Foundation of America (MesoRFA) and the Asbestos Disease Awareness Organization (ADAO) use this week to increase public awareness about the dangers of asbestos exposure and the mesothelioma treatments available for the cancer caused by asbestos particle inhalation.

On March 9, 2011, Senator Max Baucus (D-MT) and cosponsors introduced and passed US Senate Resolution 63 – 112th Congress.  This resolution (SR-63) designates the first week of April 2011 as National Asbestos Awareness Week. It urges the Surgeon General to warn and educate people about asbestos exposure, which may be hazardous to their health.  Senator Baucus began his crusade to abolish asbestos use in 1999 when he wrote a letter to then Secretary of Health and Human Services Donna Shalala requesting immediate medical help and assistance for his home state area of Libby, Montana.  Libby is a city that no one wants to live in because 1 in 8 residents has some kind of asbestos related ailments and estimates put the number of deaths related to asbestos mining at over 200.  The city once boomed from the mining of vermiculite (an asbestos containing mineral) but now it has a growing number of the town’ residents being sickened by asbestos released in the air.   The mine has been closed since 1990.

In 2002 EPA investigators found Libby, Montana to be contaminated with asbestos and began the process of containing the city.  The EPA attempted to declare a Public Health Emergency in Libby that was thwarted by the previous Federal Government Administration’s Office of Management and Budget.  Senator Baucus reported this failure in 2008, and on June 17, 2009, due in large part to Baucus’ reporting efforts, the EPA finally declared its first ever public health emergency in Libby, Montana.

Groups like MesoRFA and ADOA combine medical research, public and patient education, family advocacy and community support to compel a national and global rallying outcry for all nations to abolish asbestos mining and its use in manufactured products.  Additionally, the groups seek to increase public awareness of the suffering experienced by patients with mesothelioma with the hope to fund research and find the quickest cure to this cancer disease caused by exposure to asbestos.

Asbestos is a carcinogen to humans and exposure to it can cause diseases such as mesothelioma, lung cancer and asbestosis.  Research and studies from the World Health Organization (2004) provide estimates about asbestos-related disease from occupational exposure.  Their results counted 107,000 deaths and 1,523,000 DALYs where a Disability Adjusted Life Year (DALY) is defined as the measure of overall disease burden expressed as the number of years lost due to ill-health, disability or early death.  Other studies estimate during the next decade around the world there will be 300 deaths per day from asbestos related disease.

The ADOA will be having their 7th Annual Asbestos Awareness Conference (April 1 – 3, 2011 in Atlanta, Georgia) and will bring leading international experts together to discuss the impact of asbestos on public health, the environment, and the economy.   This organization seeks to give asbestos victims and concerned citizens a united voice to raise public awareness about the dangers of asbestos exposure. It is an independent global organization with a mission dedicated to stop asbestos use and preventing asbestos-related.

The MesoRFA compliments the ADOA objectives with their mission to fund medical research leading to the quickest cure for mesothelioma. Mesothelioma is a cancer of the lining of the lungs caused by asbestos exposure. This cancer disease had few treatment options until recent research work created better options for mesothelioma treatments with the drug, Veglin. Today, the future looks very hopeful with improved treatment to those stricken by asbestos-caused mesothelioma cancer.

Many oncologists project the average post-diagnostic malignant mesothelioma survival time in sufferers is between one and two years. Also, traditional mesothelioma treatments have had no success in eradicating the disease and have produced limited success in extending a patient’s survival time. Therefore, new and experimental mesothelioma treatments have become increasingly popular as an option for cancer sufferers.

A new approach in finding a mesothelioma cure is a drug called Veglin being studied by Dr. Gill at the USC/Norris Comprehensive Cancer Center. Veglin is one of several newly developed non-chemotherapy drugs being tested in the ongoing struggle to combat malignant mesothelioma. The new drug is an anti-angiogenesis agent that works by cutting off the blood supply that cancer cells need in order to grow. Veglin is currently in the last part of Phase II Clinical Trials with the FDA and Phase III trials should begin sometime in 2011.  Mesothelioma sufferers interested in taking part in the next clinical trial should talk with their doctor, and are encouraged to contact Dr. Parkash Gill for more information on Veglin and the trials to be had nationally.

Everyone is encouraged to participate in the national observation of Asbestos Awareness Week.  Like the American Cancer Society, Senator Max Baucus (D-MT) and non-profit groups like the Mesothelioma Research Foundation of America (MesoRFA) and the Asbestos Disease Awareness Organization (ADAO), let us all use this week to increase public awareness about the dangers of asbestos exposure and available mesothelioma treatments, because everyone wants to see less cancer and more birthdays!

Southern California Pipe Trades Finding a Cure for Mesothelioma Lung Cancer

Mesothelioma is a rare form of cancer in which malignant (cancerous) cells are found in the mesothelium, a protective sac that covers most of the body’s internal organs. Annually, the incidence of malignant peritoneal mesothelioma (MPM) is approximately 2 to 2.6 cases per million. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, such as Pipe Fitters.

Mesothelioma (cancer of the mesothelium) is a disease in which cells of the mesothelium become abnormal and divide without control or order. They can invade and damage nearby tissues and organs. Cancer cells can also metastasize (spread) from their original site to other parts of the body. Most cases of mesothelioma begin in the pleura or peritoneum.

Mesothelioma is still a relatively rare cancer, although reported incidence rates have increased in the past twenty years,. About 2,000 to 3,000 new cases of mesothelioma are diagnosed in the United States each year.

The Southern California Pipe Trades (SCPT) continues to make a significant effort to support the Mesothelioma Research Foundation of America in helping find a cure. The SCPT donated $410,000.00 at the end of 2010 to help us prepare for the Phase III Clinical Trials of our research with Veglin that will launch sometime in 2011.

Cure Mesothelioma Research funding year 2011 at $410,000.00
Southern California Pipe Trades supports the Mesothelioma Research Foundation of America

 

Donation Representatives, left-to-right
Sid C. Stopler (DC 16 Business Manager – UA Vice President District 5)
Michael Layton (DC 16 Assistant Business Manager)
Parkash Gill, M.D. (Chairman of the Medical Advisory Board)
Elizabeth Ann Paul (Executive Director of Mesothelioma Research Foundation of America)
Jerry Neil Paul (Founding Director of Mesothelioma Research Foundation of America)
John Ferruccio (DC 16 Director of Organizating)

Cure Mesothelioma Research Update
The average post-diagnostic survival time of malignant mesothelioma sufferers is between one and two years. Traditional mesothelioma treatments have had no success in eradicating the disease and have produced limited success in extending patient survival time. Therefore, new and experimental mesothelioma treatments are becoming increasingly popular options for cancer sufferers.

A new approach in finding a mesothelioma cure is a drug called Veglin being studied by Dr. Gill at the USC/Norris Comprehensive Cancer Center. Veglin is one of several newly developed non-chemotherapy drugs being tested in the ongoing struggle to combat malignant mesothelioma. The new drug is an anti-angiogenesis agent that works by cutting off the blood supply that cancer cells need in order to grow. Veglin is currently in the last part of Phase II Clinical Trials with the FDA and Phase III trials should begin sometime in 2011. More information on Veglin and the trial can be found at http://www.mesorfa.org/treatments/veglin.php. Patients interested in taking part in the next clinical trial should talk with their doctor, and contact Dr. Parkash Gill.

Interview with Dr. Parkash Gill
Dr. Gill runs the Mesothelioma Cancer Research Lab at USC/Norris Comprehensive Cancer Center and can be contacted directly at the Mesorfa.org web site.

What are this year’s plans in terms of research?
This year is going to be really exciting for Veglin and research. Veglin will be introduced into the third and final phase of the Federal Drug Administration approval process. This should all be happening by the end of the 2011 year. This will open up the patient base because the drug will be able to be administered at facilities across the United States.

What are some of the new drugs you are working on?
We have some of the brightest researchers in the nation working on finding a cure and some amazing results are coming out. Just look at Veglin. The new drugs mentioned in previous articles and newsletters, EPH-B4 and Delta, are showing great promise of following in Veglin’s footsteps. There is still much work to be done but the lab results coming from combinations, of say Veglin with Delta, or Delta with EPH-B4, are better than I could have ever hoped. We are very close, but like I said there is much work to be done.